The goal of this study was to investigate possible differences in thrombin generation or fibrinolytic capacity in patients with unstable angina (UA) or acute myocardial infarction (AMI) with or without recurrent angina at rest. BACKGROUND Angina at rest in patients with AMI or UA is generally produced by a reduction in coronary flow, but it is unclear whether patients with or without this event differ in their thrombin generation or in their fibrinolytic capacities, which might influence the course of the culprit lesion.
Angina at rest while in the hospital is a complicating event in patients with either unstable angina (UA) or acute myocardial infarction (AMI). Advanced coronary artery disease (1-4) and a reduced coronary reserve are associated with an increased incidence of recurrent episodes that are mostly related to transient decreases in coronary flow (5, 6) . They appear to be favored by temporal decreases in ischemic See page 2044 threshold that have been attributed to increases in coronary tone, which tend to follow a circadian pattern (7, 8) . It is unclear, however, whether abnormalities in the fibrinolytic activity or in the formation of thrombin may also contribute to the persistence of an unstable condition allowing the persistence of an active thrombus overlying the complicated plaque or fissure (9) . In addition, it is also unknown whether these hypothetical abnormalities are similarly present in patients with UA and in those with AMI and whether they persist during hospitalization or in the early follow-up. Since plasminogen activator inhibitor, type 1 (PAI-1) and tissue plasminogen activator act in concert to regulate plasminogen conversion to plasmin, their levels are indirect markers of the fibrinolytic activation (10) . Indeed, a decreased fibrinolytic activity demonstrated by a prolonged lysis time is accompanied by elevated PAI-1 antigen levels (11, 12) , and plasmin formation is strongly dependent on PAI-1 levels (12) . On the other hand, fibrin D-dimer indicates intravascular turnover of fibrin by identifying a primary degradation product of cross-linked fibrin. Thus, it is a direct marker of endogenous fibrinolysis (10) , and it is found in conditions associated with intravascular activation of the coagulation process (13) . Moreover, thrombinantithrombin complex (TAT) is a reliable indicator of ongoing thrombin formation. Thus, the aims of this study were to analyze in patients with a first episode of UA or a first episode of AMI the possible changes in plasma levels of fibrinogen, TAT, d-dimer and PAI-1 during hospitalization and at 3 months of follow-up and to assess the possible differences between those who develop recurrent angina at rest and those who do not.
METHODS

Patients.
The study population consisted of 77 patients admitted to our coronary care unit, 48 with AMI and 29 with UA. The clinical diagnosis of AMI was based on the concurrence of chest pain, elevated myocardial enzymes (total and MB creatine kinase above twice the upper normal limit) and electrographic changes (ST segment elevation or depression). Diagnosis of UA included the presence of typical angina at rest associated with acute and transient ST segment or T wave changes, with or without progressive exercise-induced angina without enzyme elevation. Exclusion criteria were: age Ͼ75 years, presence of Killip class III or IV, left bundle branch block, associated cardiac diseases, previous myocardial infarction, hospital admission for UA, coronary artery bypass grafting or coronary angioplasty. Twenty-six nonsmokers and healthy individuals, age 47 Ϯ 5 years, constituted the control group. Study protocol. Patients were treated with intravenous heparin to maintain a partial thromboplastine time approximately twice the control value during the first 2 to 6 days and with aspirin, 250 mg orally. Those with UA and those with AMI who presented recurrent angina also received intravenous nitroglycerin and beta-adrenergic blocking agents. In patients with AMI beta-blockers were initiated during the first five days. Calcium antagonists were added if recurrent angina persisted. During the follow-up patients from both groups received aspirin 250 mg daily and most also received beta-blockers. Those with occasional angina also received nitrates or calcium antagonists. The protocol was approved by the Hospital ethics committee, and informed consent was obtained before entering the study. Blood sampling. All patients underwent venous blood sampling on the first 24 h after initiation of intravenous heparin and also on days 10 through 12 and at three months of follow-up. In patients who received thrombolytic therapy, the first sample was drawn before its administration. Samples were drawn between 8:30 and 9:30 AM in a fasting condition without vascular compression and with the patient lying in bed for at least the preceding 30 to 45 min. The first 3 ml of blood were discarded; then, 4.5 ml of blood and 0.5 ml of sodium citrate (0.13 M) for TAT, D-dimer and fibrinogen measurements were mixed, and 5 ml of blood were placed in a diatube for PAI-1 measurements. Samples were then centrifuged at 2,000 g for 20 min at 4°C, and the citrated tube was stored at Ϫ80°C until analyzed. Laboratory methods. Enzyme-linked immunosorbent assays were used to determine plasma concentrations of PAI antigen (Tintelize PAI-1, Biopool, Sweden), TAT (Enzysnost TAT Micro, Behring, Marbourg, Germany) and D-dimer (Fibrinostika FbDP, Organon Teknika, Boxtel, the Netherlands). Fibrinogen plasma levels were measured by the Von Clauss coagulative method. The lower limits of detection and the co-efficient of variation for PAI-I antigen were 0.5 ng/ml and 6%; for TAT they were 0.5 g/l and 8.9%; for D-dimer they were 11 ng/ml and 14%, and for fibrinogen they were 0.2 g/l and 4.8%, respectively. Coronary angiography. Of the initial 77 patients, 14 were excluded because of lack of some blood samples (n ϭ 4), inadequate sampling technique (n ϭ 3) or need for coumadin therapy (n ϭ 2) or coronary surgery (n ϭ 5). Thus, a total of 63 patients, 23 with UA and 40 with AMI, were finally included. A coronary angiography was performed during hospitalization in 51, in 38 within the first 10 days and in 13 beyond day 10, and a contrast left ventriculogram was performed in 47. Technical restrains, or patient refusal prevented performance of cardiac catheterization in 12. A Ͼ70% stenosis of a major coronary vessel was considered significant. Statistical analysis. The chi-square test or the Fisher exact test was used to compare categoric variables. The intragroup and intergroup (interaction term) differences for continuous variables were assessed using analysis of two-way repeated measures, analysis of variance. The student t test for unpaired samples was used for intergroup differences between one time measurements. The data are expressed as mean Ϯ standard deviation.
RESULTS
Clinical and angiographic data. Table 1 summarizes most relevant information. Fifteen patients with AMI received thrombolytic therapy, and 22 (34.9%), 10 with AMI and 12 with UA, developed angina at rest while in the hospital (1.9 Ϯ 2.3 episodes for UA and 0.5 Ϯ 0.9 for AMI). Patients with in-hospital angina were comparable to those without except for a lower incidence of smoking and a higher incidence of antecedent angina (Ͼ1 month). They also had a higher ejection fraction, in part accounted for by the lower proportion of patients with AMI ( declined significantly in the follow-up (Tables 2 and 3) . At the three stages values were similar in the two groups and were significantly higher than they were in the control group (2.9 Ϯ 0.4 g/l, p Ͻ 0.005). Patients with in-hospital angina showed similar values than those who remained asymptomatic, either when considering all patients (Fig. 1 ) or only those with AMI or UA (Table 3) . Although first day values were higher in asymptomatic patients with AMI, intergroup analysis showed no significant differences (Fig. 1 , Tables 2  and 3) . Thrombin-antithrombin complex values were highest at 10 days in AMI patients, and they showed a similar trend in those with UA (Tables 2 and 3 ). Values at the three stages were comparable in the two groups and were significantly higher than they were in the control group (3.4 Ϯ 1.4 g/l, p Ͻ 0.005). For all 63 patients values at 10 days were higher in those with in-hospital angina than they were in those without (p Ͻ 0.013, Fig. 1 ). Among patients with UA those who remained unstable while in the hospital had higher values at 3 months than those who remained asymptomatic (Tables 2 and 3 ). Intergroup analysis showed no significant differences except for a trend towards significance in the overall comparison between patients with or without inhospital angina (p Ͻ 0.077, Fig. 1 ).
In patients with AMI measurements of PAI-1 were highest on the first day, and a similar trend was observed in those with UA. First day and 10 day levels were comparable in the two subsets (Tables 2 and 3) . For all 63 patients (Fig. 2), as well as for each of the two subsets (Tables 2 and 3) , those with in-hospital angina had higher first day values than those who remained asymptomatic. Intergroup analysis revealed a significant difference for the overall group (p Ͻ 0.029, Fig. 2) . Also, first day values of PAI-1 were Ͼ50 ng/ml in 16 of 22 patients with in-hospital angina (72.7%) and in 14 of 41 without (34.1%, p Ͻ 0.01) and were significantly higher than those in the control group (27.3 Ϯ 24.2, p Ͻ 0.001).
In patients with AMI or UA first day values for D-dimer (Tables 2 and 3 ) were higher than they were in the control group (273 Ϯ 78 ng/ml, p Ͻ 0.02 and p Ͻ 0.01, respectively). At 10 days they increased significantly, and at each of the three stages values were comparable in the two subsets (Tables 2 and 3) . When considering all patients, those with recurrent angina had a greater increase in D-dimer at 10 days than those without (p Ͻ 0.004, Fig. 2) . A similar trend occurred in the two groups although in the UA group the difference was of borderline significance (Tables 2 and 3 ). Intergroup analysis showed significant differences for the overall group (p Ͻ 0.029, Fig. 2 ) and for the group with UA (Table 3) . Values Ͼ600 ng/ml were present in 18 of 22 patients with in-hospital angina (81.8%) and in 24 of 41 of those who remained asymptomatic (58.5%, p Ͻ 0.054).
In 54 of 63 patients (83.7%) the 10th day sample was taken either before coronary angiography or 4 days after the procedure, whereas in the remaining nine sampling was Table 2 .
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Angina at Rest and Fibrinolytic Activity performed 24 to 72 h after the procedure. Thus, in the 38 patients who underwent catheterization within the first 10 days, the interval between catheterization and the 10th day sampling was 5.0 Ϯ 2.3 days. Moreover, at 10 days patients were no longer receiving heparin, which had been discontinued within the first four to five days in most of them.
DISCUSSION
Fibrinogen and TAT measurements. Consistent with previous observations (14 -16) patients with AMI or UA had higher fibrinogen levels on the first day than did a control population. In addition we noted a further increase at 10 days similar to that reported by Aznar et al. (17) , and that might be attributable to an acute phase reaction (18 -20) . More specifically, however, we demonstrated that these values were comparable in the two subsets. We also observed that TAT levels increased during hospitalization to a similar extent in the two groups. The results in patients with UA are in line with those reported by Hoffmeister et al. (23), who also found increases in TAT levels during hospitalization. These investigators (21-23), however, limited their measurements to the first days, had no early follow-up data and did not compare the results of UA patients with the results of patients with AMI (22, 23) . In our study the increases in thrombin generation at 10 days corresponding to the increases in TAT declined at three months but remained higher than they did in control subjects. Similarly, Merlini et al. (24) documented that patients with UA or AMI had a persistent hypercoagulable state at six months of followup. . Also shown are values from a control group. Thrombin-antithrombin complex values at the three stages were higher in patients than they were in the control group (see text). There were significant (*) intragroup differences (ANOVA) in the two subsets as well as a trend towards intergroup differences (ANOVA, p Ͻ 0.077), mainly because of the higher values at 10 days in patients with in-hospital angina than in those without (p Ͻ 0.013). Fibrinogen levels were also higher in patients than they were in the control group and increased significantly at 10 days to a comparable extent in patients with or without in-hospital angina. Intragroup differences (ANOVA) were significant (*). ANOVA ϭ analysis of variance. values at the three stages were higher in patients than they were in the control group (see text). There were significant intragroup differences (*) (ANOVA) in the two subsets as well as intergroup differences (ANOVA, p Ͻ 0.029). At 10 days values were significantly higher in patients with in-hospital angina than they were in those without (p Ͻ 0.004). Plasminogen activator inhibitor, type 1 levels were also higher in patients than they were in the control group, and there were significant (*) intragroup (ANOVA) as well as intergroup differences (ANOVA, p Ͻ 0.029). The latter were mainly related to the particularly higher PAI-1 levels on day one in patients who developed in-hospital angina than in those who did not (p Ͻ 0.008). ANOVA ϭ analysis of variance; PAI-1 ϭ plasminogen activator inhibitor, type 1. PAI-1 and D-dimer measurements. Another observation of interest was the higher PAI-1 levels found on day one than at 10 days or at the three months of follow-up. Even though this was more apparent in patients with AMI, those with UA also had higher first day than 10 day values, indicating that both groups had a reduced PAI-1 related fibrinolytic activity during at least the first 24 h. In patients with UA, Hoffmeister et al. (21) also found increased levels of PAI-1 but did not document a decline at 10 days and Al-Nozha et al. (22) also observed increased levels during the first five days but did not examine possible changes later on. Moreover, these authors did not investigate possible differences between patients with or without recurrent angina (21, 22) . In contrast with these studies Alexopoulos et al. (25) found no change in PAI-1 levels within first 24 h to 48 h in similar patients. In patients with AMI Sakamoto et al. (26) observed, as in our study, a transiently reduced fibrinolytic capacity that became normal a few weeks after discharge, but the study did not assess possible changes during the hospital course or differences between patients with or without recurrent angina. Also worthwhile was the significant in-hospital increase in plasma D-dimer levels in patients with AMI or UA. Similar increases had been previously reported by some investigators in patients with AMI (27, 28) or UA (21, 28) but not by others (25, 29) . Although Kruskhal et al. (28) performed only a single measurement and within 1 h of chest pain in patients with UA or AMI, they showed similar levels of D-dimer as our first day values (28) . Moreover, we observed a further increase at 10 days that was not documented by Hoffmeister et al. (21) . Among patients with AMI, increases in D-dimer are known to occur (28, 29) and appear to be particularly elevated in those with heart failure or ventricular arrhythmias (30) . Of interest is that Takano et al. (31) observed that, in patients with atherothrombotic strokes, D-dimer values were significantly higher at seven days than on day one, as in our patients with AMI or UA. Influence of clinical instability. Previous investigations that have analyzed TAT (21-23), PAI-1 (21, 22) or D-dimer levels (21) in patients with UA have not evaluated possible differences between those with or without recurrent in-hospital angina. This is relevant because our patients who experienced episodes of angina at rest despite full medical therapy differed in these parameters from those who remained stable. Thus, even though both subsets, stable and unstable, presented an increased rate of thrombin formation at 10 days as indicated by the higher levels of TAT and D-dimer, which are probably associated with increases in other markers of acute phase reactants such as fibrinogenseen in this study and by others (17)-C-reactive protein (32) (33) (34) or von Willebrand factor (34, 35) , the change was more remarkable in the unstable group. This group also had higher levels of PAI-1 on the first day than those who remained asymptomatic, and they had a greater fall on day 10. The difference between these findings and those of Hoffmeister et al. (21) who failed to find a decline of PAI-1 at 10 days may possibly lie in the differences in the clinical course because they excluded patients with recurrent angina. At variance with these studies, however, Alexopoulos et al. (25) found no change in PAI-1 levels within first 24 h to 48 h and failed also to find differences between patients with or without recurrent angina. Although it is unclear why our results differ from theirs, for one thing the population and study design were different (25) . In fact, their patients were older, had more women, some had had previous coronary events, and the analysis of the recurrence of angina was limited to the first 48 h (25). Moreover, PAI-1 antigen was measured by a different technique, samples were not systematically obtained at the same hour and, as opposed to previous observations (36), they encountered no circadian differences in PAI-1 levels. As indicated, failure to note further increases in D-dimer at 10 days by Hoffmeister et al. (21) could presumably be attributed to the exclusion of patients with recurrent angina. Thus, their results in stable "unstable" patients would be in agreement with those of our stabilized patients who showed lower values of D-dimer at 10 days than those who remained unstable.
Hypothetically, the increased in-hospital thrombin generation and D-dimer levels seen in patients with recurrent angina could possibly be linked, in part, to coincidental episodes of silent ischemia, like the changes in TAT levels documented by Biassucci et al. (37) . However, at 10 days the majority of our patients with recurrent angina had already attained a stable course. Therefore, in view of the consistent increases in TAT and D-dimer levels at 10 days on one hand and of their short plasma half-life (5 min for TAT [38] and 4 to 8 h for D-dimer [28, 39] ) on the other, we are more inclined to interpret these changes as originating from a steady source, such as the inflammatory reaction that accompanies this unstable condition (16, 40, 41) than to an unpredictable source such as asymptomatic episodes of ischemia.
Another reliable marker of thrombin activity in plasma, the fibrinopeptide A, has also been shown to increase in patients with UA who experience in-hospital angina associated with ST segment changes (29) or intracoronary thrombus (42) . Moreover, increased fibrinopeptide A levels have been documented in patients with UA who developed an AMI during the hospitalization (43) .
It is unclear why our patients with AMI and recurrent angina had a lower initial fibrinolytic activity than those who remained stable since, apparently, the former subset would tend to have a less occlusive thrombus. Thus, it is conceivable that the observed systemic alterations in thrombin formation and in fybrinolitic status would be independent of the characteristics of the thrombus of the culprit artery and might be secondary to a more generalized response, such as the alluded systemic inflammatory reaction. Accordingly, it is possible that unstable patients after an AMI would present a greater inflammatory response than the stable ones, as in patients with UA who remain symptomatic (33) . Moreover, our patients with AMI and Angina at Rest and Fibrinolytic Activity recurrent angina had a larger incidence of preinfarction angina than those without angina, which is in agreement with previous reports (3, 44) . In this regard, it is of interest that tissue factor plasma levels, which are a primary initiator of the extrinsic coagulation cascade, have been shown to be higher in patients with AMI who experienced UA previously as compared with those who did not (45) . Study limitations. The use of heparin during first day samples may be considered as a limitation to assess coagulation alterations. However, we deemed it of interest since it is a widely used treatment, and, hence, the potential prognostic implications derived from these initial findings could be applicable to patients with standard therapy. In previous studies, Hoffmeister et al. (21) and Al-Nozah et al. (22) also included patients treated with heparin and assumed, as we did, that TAT levels could have been somewhat higher without this antithrombin therapy. This effect, however, would be similar in all our subsets of patients. In addition, and while heparin reduces thrombin formation and fibrinopeptide A levels-which is a specific product of fibrinogen cleavage by thrombin-its effects on D-dimer levels seem to be negligible (27) . On the other hand, 10 day TAT values could have been influenced by heparin discontinuation for this is a condition associated with a rapid increase in fibrinopeptide A (46) and thrombin generation. However, this is a short duration phenomenon with a return to baseline values at 24 h (47), and, consequently, it is unlikely to have altered our 10 day samples because they were taken at an average of five days after heparin cessation. Another potential limitation is the possible interference by the catheterization and angioplasty procedures with the natural evolution of thrombin generation and fibrinolytic activity. Indeed, the higher need for catheterization or angioplasty in the unstable group and the possible link between these procedures and the activation of thrombin formation (48, 49) could have partly accounted for their higher values. However, it was precisely to circumvent this interference and that of the variable use of heparin during the first days that the second samples were drawn at 10 days, which is a time when most patients have already stabilized. Although there are no studies analyzing the changes in the parameters herein reported after catheterization, there appears to be a striking increase in C-reactive protein and interleukin 6 after percutaneous transluminal coronary angioplasty or coronary angiography, but only in UA patients with high levels of C-reactive protein and interleukin 6 before the procedures and not in those with normal levels or those with stable angina (49) . These values, however, return to baseline in 72 h (49) . Among our patients only nine (14%) had their angiography/percutaneous transluminal coronary angioplasty performed between the 24 h to 72 h before the 10th day sample, and five of them belong to the stable subset. Moreover, since TAT and D-dimer have a much shorter half-life than C-reactive protein, 5 min (38) and 5 h to 8 h (28,39) versus 19 h (49), it seems improbable that catheterization procedures could have significantly influenced the changes observed in most of our patients.
Admittedly, the fact that our group of healthy controls was younger than our patients subsets constitutes a limitation. Thus, even though other groups have found similar differences between patients and controls (14 -16,21) , it is possible that the magnitude of our differences might not be comparable with those of age-matched control studies. Hence, our data need to be interpreted with caution. Moreover, the relevance of our results with respect to the incidence of infarction is very limited since the number of patients studied is reduced. Nevertheless, there might be a link with our findings because recurrence of angina appears to be a good predictor of subsequent infarction (2) (3) (4) 44, 50) . Finally, we evaluated only symptomatic recurrent ischemia and provided no information about silent ischemia. Thus, theoretically, there is a possibility that, by analyzing asymptomatic rather than symptomatic ischemia, the results could have been different. However, silent ischemia is much more likely to occur among patients with recurrent angina than it would in those who remain asymptomatic (2, 5, 51) . Clinical implications. Our study extends previous observations on the persistence of a hypercoagulative state in patients with UA or AMI. It adds, however, that this becomes more apparent among patients with either UA or AMI who remain unstable in the hospital. This subset, moreover, already shows a particularly reduced fibrinolytic capacity on admission. These findings, therefore, may shed further light into the mechanisms of angina at rest in the context of UA or AMI. They may suggest that the persistence of a hypercoagulative condition may perhaps limit the ability to reduce the size of the thrombi at the culprit lesion and, hence, may facilitate additional deposition of fibrin or platelet aggregates. The association with transient increases in coronary tone, which seem to follow a circadian pattern (8) , would further reduce coronary flow leading to myocardial ischemia. Our results, therefore, would be in concert with the concept that a better control of thrombin generation, and possibly of platelet aggregation, will eventually contribute to a better prevention of recurrent angina in at least a number of these patients.
